Replies to post #382706 on Amarin Corp Plc (AMRN)

[Whalatane]

DOGN. RESPECT EPA is only in a Japanese population and looks designed to try and reproduce these results among a sub population in the original JELIS ....by enrolling only these types of patients ...prior MI , CABG etc

Among the 895 patients with prior coronary intervention (PTCA or CABG), the incidence of MCE in the EPA group (14.7%) was signifcantly lower than that in the control group (22.0%, adjusted HR 0.65, P=0.007, NNT =13, Figure 2b).

Among the 1,050 patients with prior MI, the incidence of MCE in the EPA group (15.0%) was signifcantly lower than that in the control group (20.1%, adjusted HR 0.73, P= 0.033, NNT =19,

MITIGATE will be a similar population ...established ASCVD with a lot of prior MI's , PCI ( stents ) and CABG ( bypass )

Neither of these trials has a mineral oil placebo ...so if the results are similar ( altho MITIGATE will be a shorter trial so may only show trend towards ) ... to the quoted area above ...that ends the MO debate

Kiwi